Figure 1.

Immune biomarker identification: key points in the process. (a) Culture cells from lymph nodes derived from stage III melanoma patients. Schematic of tumor and tumor microenvironment. (b) Table of the treatments to which the cells in a were exposed. (c) Identification of parameters that discriminate patients as ‘Responder’ vs ‘Non-responders’ to anti-PD-1, anti-CTLA-4 and both among the conditions evaluated in b. (d) Retrospective validation of the parameters identified in c in the blood of resected stage IIIc and IV melanoma patients from a phase 2 adjuvant trial of ipilimumab plus nivolumab.